Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Moderna Inc
(NQ:
MRNA
)
63.64
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Moderna Inc
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Moderna to Host First Environmental, Social and Governance (ESG) Day on November 10, 2022
October 27, 2022
Via
ACCESSWIRE
Moderna Named a Top Employer by Science for Eighth Consecutive Year
October 27, 2022
Via
ACCESSWIRE
Moderna Stock Went Up Because It Is Joining Hands With the US to Make Shots to Fight Ebola and Other Threats
October 26, 2022
Moderna Stock (NASDAQ:MRNA) On Wednesday, Moderna stock (NASDAQ:MRNA) increased after Bloomberg reported that the business and the United States Department of Defense is close to inking an agreement to...
Via
PressReach
EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Authorization Of Moderna's Omicron BA.4-BA.5 Targeting Bivalent Covid-19 Vaccine In The European Union
October 19, 2022
Via
ACCESSWIRE
EMA Committee for Medicinal Products for Human Use Issues Positive Opinion Recommending Authorization for the Use of Spikevax (mRNA-1273) in Children 6 Months - 5 Years in the European Union
October 19, 2022
Via
ACCESSWIRE
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Children and Adolescents 6 to 17 Years of Age
October 12, 2022
Via
ACCESSWIRE
Moderna Creates New Executive Committee Role Ahead of New Product Launches
September 29, 2022
Via
ACCESSWIRE
Indonesia's Bio Farma ready to produce IndoVac Covid-19 vaccines
September 13, 2022
Via
JCN Newswire
Exposures
COVID-19
90-Day Analysis Shows Moderna’s Omicron BA.1-Targeting Bivalent Vaccine, mRNA-1273.214, Demonstrates Superior Antibody Response as Fourth Booster Compared to Spikevax Prototype Booster
October 19, 2022
Via
ACCESSWIRE
Merck Nears Breakout Point After October Surprise Good News
October 19, 2022
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments.
Via
MarketBeat
Topics
Stocks
Exposures
US Equities
Moderna Announces Update to 2022 Supply Agreement with Gavi that Secures Access to Updated Variant-Specific COVID-19 Vaccines for Low-and-Middle Income Countries
October 17, 2022
Via
ACCESSWIRE
Moderna to Report Third Quarter 2022 Financial Results on Thursday, November 3, 2022
October 13, 2022
Via
ACCESSWIRE
Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine
October 12, 2022
Via
ACCESSWIRE
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
September 08, 2022
Via
ACCESSWIRE
Health Canada Authorizes Moderna's Omicron-Targeting Bivalent COVID-19 Booster Vaccine
September 01, 2022
Via
ACCESSWIRE
Moderna to Host R&D Day on Thursday, September 8, 2022
August 29, 2022
Via
ACCESSWIRE
Moderna exercises option to license proprietary targeting technology from Autolus
October 12, 2022
From
Autolus Therapeutics plc
Via
GlobeNewswire
Is Pfizer Stock Still Worth Buying After the Pandemic?
October 12, 2022
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.
Via
MarketBeat
Exposures
COVID-19
European Medicines Agency Accepts Moderna's Conditional Marketing Authorization Filing for its Omicron BA.4/BA.5 Targeting Bivalent COVID-19 Vaccine
September 28, 2022
Via
ACCESSWIRE
Novavax Remains a Risk-On Stock in a Risk-Off Market
September 22, 2022
NVAX is a risk-on stock at a time investors are turning to risk-off assets. This article looks to see if Novavax still presents an opportunity for investors
Via
MarketBeat
Topics
Earnings
Exposures
Financial
Swissmedic Authorizes Moderna’s Omicron-Targeting Bivalent Booster Candidate, MRNA-1273.214
August 29, 2022
Via
ACCESSWIRE
Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna's Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214
September 12, 2022
Via
ACCESSWIRE
Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines
September 12, 2022
Via
ACN Newswire
Exposures
COVID-19
Indonesian pharmaceutical Bio Farma ready to produce IndoVac Covid-19 vaccines
September 09, 2022
Via
ACN Newswire
Exposures
COVID-19
Moderna to Present at the Morgan Stanley 20th Annual Global Healthcare Conference
September 06, 2022
Via
ACCESSWIRE
EMA Committee for Medicinal Products for Human Use (CHMP) Adopts Positive Opinion Recommending Authorization for the Use of Moderna's Omicron-Targeting Bivalent Booster in the European Union
September 01, 2022
Via
ACCESSWIRE
Moderna Receives FDA Authorization for Emergency Use of Omicron-Targeting Bivalent COVID-19 Booster Vaccine for Adults 18 Years and Older
August 31, 2022
Via
ACCESSWIRE
Therapeutic Goods Administration Provisionally Approves Moderna’s Omicron-Containing Bivalent Booster Candidate, MRNA-1273.214, For Australia
August 30, 2022
Via
ACCESSWIRE
Moderna Sues Pfizer and BioNTech for Infringing Patents Central to Moderna's Innovative mRNA Technology Platform
August 26, 2022
Via
ACCESSWIRE
Moderna Completes Application To U.S. Food And Drug Administration For Emergency Use Authorization Of Omicron-Targeting Bivalent Covid-19 Booster Vaccine, mRNA-1273.222
August 23, 2022
Via
ACCESSWIRE
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.